Experimental drug shows promise in Huntington’s

A metal protein-attenuating compound may improve cognitive performance in patients with Huntington’s disease, according to research carried out at US and Australian centres.

Published in the Lancet Neurology, the phase 2 study randomised 109 people with early- to mid-stage Huntington’s to six months of the drug PBT2 (250mg or 100mg daily) or to placebo.

The drug was well tolerated and found to be safe, which were the

Latest

Trending